At the time of writing, Cullinan Therapeutics Inc [CGEM] stock is trading at $12.93, up 36.54%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CGEM shares have gain 47.43% over the last week, with a monthly amount glided 66.62%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On October 24, 2024, UBS initiated with a Buy rating and assigned a price target of $30 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $40 on May 01, 2024. William Blair initiated its recommendation with an Outperform. Wedbush started tracking with an Outperform rating for this stock on February 15, 2024, and assigned it a price target of $30. In a note dated June 15, 2023, TD Cowen initiated an Outperform rating.
For the past year, the stock price of Cullinan Therapeutics Inc fluctuated between $5.68 and $13.78. Currently, Wall Street analysts expect the stock to reach $32 within the next 12 months. Cullinan Therapeutics Inc [NASDAQ: CGEM] shares were valued at $12.93 at the most recent close of the market. An investor can expect a potential return of 147.49% based on the average CGEM price forecast.
Analyzing the CGEM fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.42 and Total Capital is -0.53. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.56 points at the first support level, and at 8.18 for the second support level. However, for the 1st resistance point, the stock is sitting at 14.32, and for the 2nd resistance point, it is at 15.70.
Ratios To Look Out For
It is important to note that Cullinan Therapeutics Inc [NASDAQ:CGEM] has a current ratio of 10.45. In addition, the Quick Ratio stands at 10.45 and the Cash Ratio stands at 3.15.
Transactions by insiders
Recent insider trading involved JENNIFER MICHAELSON, Officer, that happened on Nov 24 ’25 when 4000.0 shares were purchased. 10% Owner, Lynx1 Capital Management LP completed a deal on Oct 28 ’25 to buy 0.17 million shares. Meanwhile, 10% Owner Lynx1 Capital Management LP bought 0.15 million shares on Oct 16 ’25.
